Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page
- Check2 days agoChange DetectedSite updated to version v3.4.2. The prior government funding notice was removed; there are no changes to the trial details or page data.SummaryDifference0.5%

- Check9 days agoChange DetectedA site-wide notice about government funding affecting updates was added, and the site version was updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check17 days agoChange DetectedMinor UI/copy updates include showing the glossary option, capitalization tweaks in the QC criteria wording, and a new revision/version line. These changes are cosmetic and do not affect study content or navigation.SummaryDifference0.2%

- Check24 days agoChange DetectedThe only visible change is a revision label update from v3.3.3 to v3.3.4; there are no observed modifications to study details, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded a Locations section listing Pennsylvania as a study site. Removed the HHS Vulnerability Disclosure link and updated the page revision to v3.3.3.SummaryDifference0.2%

- Check74 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page, an internal version update that does not modify study content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.